Page 1296 - Williams Hematology ( PDFDrive )

1270 Part IX: Lymphocytes and Plasma Cells Chapter 82: Mononucleosis Syndromes 1271

71. Zaadstra BM, Chorus AM, van Buuren S, et al: Selective association of multiple sclero- 104. Davis JE, Moss DJ: Treatment options for post-transplant lymphoproliferative
sis with infectious mononucleosis. Mult Scler 14:307, 2008. disorder and other Epstein-Barr virus associated malignancies. Tissue Antigens 63:285,
72. James JA, Neas BR, Moser KL, et al: Systemic lupus in adults associated with previous 2004.
Epstein-Barr virus exposure. Arthritis Rheum 44:1122, 2001. 105. Farrell CJ, Lee JM, Shin EC, et al: Inhibition of Epstein-Barr virus–induced growth
73. Harley JB, Harley IT, Guthridge JM, James JA: The curiously suspicious: A role of proliferation by nuclear antigen EBNA-2 peptide. Proc Natl Acad Sci U S A 101:4625,
Epstein-Barr virus in lupus. Lupus 15:768, 2006. 2004.
74. Lunemann JD, Frey O, Eidner T, et al: Increased frequency of EBV specific effector 106. Weller TH, Hanshaw JB: Virologic and clinical observations in cytomegalic inclusion
memory CD 8+ T cells correlates with higher viral load in rheumatoid arthritis. disease. N Engl J Med 266:1233, 1962.
J Immunol 181:991, 2008. 107. Hanshaw, JB, Betts RF, Simon G, Boynton RC: Acquired cytomegalovirus infection. N
75. Kawano Y, Iwata S, Kawada J, et al: Plasma viral microRNA profiles reveal potential Engl J Med 272:602, 1965.
biomarkers for chronic active Epstein-Barr virus infection. J Infect Dis 208:771, 2013. 108. Klemola E, Von Essen R, Henle G, et al: Infectious mononucleosis like disease with
76. Buchwald DS, Rea TD, Katon WJ, et al: Acute infectious mononucleosis: Characteris- negative heterophile agglutinin test. Clinical features in relation to Epstein-Barr virus
tics of patients who report failure to recover. Am J Med 109:531, 2000. and cytomegalic virus antibodies. J Infect Dis 121:808, 1970.
77. Okano M: Overview and problematic standpoints of severe chronic active Epstein-Barr 109. de Vries JJ, van Zwet EW, Dekker FW, et al: The apparent paradox of maternal sero-
virus infection syndrome. Crit Rev Oncol Hematol 44:273, 2002. positivity as a risk factor for congenital cytomegalovirus infection: A population-based
78. Suzuki K, Ohshima K, Karube K, et al: Clinicopathological states of Epstein-Barr prediction model. Rev Med Virol 23:241, 2013.
virus-associated T/NK cell proliferative disorders (severe chronic active EBV infection) 110. Stagno S, Pass RF, Dworsky ME, et al: Congenital cytomegalovirus infection: The rel-
of children and young adults. Int J Oncol 24:1165, 2004. ative importance of primary or recurrent maternal infection. N Engl J Med 306:945,
79. Chen CJ, Huang YC, Jaing TH, et al: Hemophagocytic syndrome: A review of 18 pedi- 1982.
atric cases. J Microbiol Immunol Infect 37:157, 2004. 111. Just-Nubling G, Korn S, Ludwig B, et al: Primary cytomegalovirus infection in an out-
80. Imashuku S, Kuriyama K, Sakai R, et al: Treatment of Epstein-Barr virus-associated patient setting—Laboratory markers and clinical aspects. Infection 31:318, 2003.
hemophagocytic lymphohistiocytosis (EBV-HLH) in young adults: A report from HLH 112. Söderberg-Nauclér C, Fish KN, Nelson JA: Reactivation of latent human cytomegalovi-
study center. Med Pediatr Oncol 41:103, 2003. rus by allogeneic stimulation of blood cells from healthy donors. Cell 91:119, 1997.
81. Imashuku S, Teramura T, Tauchi H, et al: Longitudinal follow-up of patients with 113. Smith MS, Bentz GL, Alexander JS, Yurochko AD: Human cytomegalovirus induces
Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Haematologica monocyte differentiation and migration as a strategy for dissemination and persistence.
89:183, 2004. J Virol 78:4444, 2004.
82. Pagano JS: Epstein-Barr virus. The first human tumor virus and its role in cancer. Proc 114. Betts RF, Freeman RB, Douglas RG Jr, et al: Transmission of cytomegalovirus with the
Assoc Am Physicians 111:573, 1999. renal allograft. Kidney Int 8:385, 1975.
83. Endo R, Kikuta H, Ebihara T, et al: Possible involvement in oncogenesis of a single base 115. Ho M, Suwansirkul S, Dowling JN, et al: The transplanted kidney is a source of
mutation in internal ribosome entry site of Epstein-Barr nuclear antigen 1 mRNA. J cytomegalovirus infection. N Engl J Med 293:1109, 1975.
Med Virol 72:630, 2004. 116. Betts RF, Freeman RB, Douglas RG Jr, Talley TE: Clinical manifestations of renal allog-
84. Flavell KJ, Murray PG: Hodgkin disease and Epstein-Barr virus. Mol Pathol 53:262, raft derived primary cytomegalovirus infection. Am J Dis Child 131:759, 1977.
2000. 117. Drew WL, Mintz L, Hoo R, Finley TN: Growth of herpes simplex and cytomegalovirus
85. Hjalgrim H, Askling J, Rostgaard K, et al: Characteristics of Hodgkin’s lymphoma after in cultured human alveolar macrophages. Am Rev Respir Dis 119:287, 1979.
infectious mononucleosis. N Engl J Med 349:1324, 2003. 118. Chien J, Chan CK, Chamberlain D, et al: Cytomegalovirus pneumonia in allogeneic
86. Hjalgrim H, Rostgaard K, Johnson PC, et al: HLA-A alleles and infectious mononucle- bone marrow transplantation. An immunopathologic process? Chest 98:1034, 1990.
osis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lym- 119. Huisman C, van der Straaten HM, Canninga-van Dijk MR, et al: Pulmonary com-
phoma. Proc Natl Acad Sci U S A 107:6400, 2010. plications after T-cell-depleted allogeneic stem cell transplantation: Low incidence
87. Kanakry JA, Li H, Gellert LL, et al: Plasma Epstein-Barr virus DNA predicts outcome and strong association with acute graft-versus-host disease. Bone Marrow Transplant
in advanced Hodgkin lymphoma: Correlative analysis from a large North American 38:561, 2006.
cooperative group trial. Blood 121:3547, 2013. 120. Snyder LD, Finlen-Copeland CA, Turbyfill WJ: Cytomegalovirus pneumonitis is a risk
88. Gao SZ, Chapparro SV, Perlroth M, et al: Post-transplant lymphoproliferative disease in for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care
heart and heart-lung transplant recipients: 30 year experience at Stanford University. J Med 181:1391, 2010.
Heart Lung Transplant 22:505, 2003. 121. Ljungman P: Cytomegalovirus infections in transplant patients. Scand J Infect Dis Suppl
89. Ballen KK, Cutler C, Yeap BY, et al: Donor-derived second hematologic malignancies 100:59, 1996.
after cord blood transplantation. Biol Blood Marrow Transplant 16:1025, 2010. 122. Schooley RT, Hirsch MS, Colvin RB, et al: Association of herpes virus infections with
90. McDonald RA, Smith JM, Ho M, et al: Incidence of PTLD in pediatric renal transplant T-lymphocyte subset alterations, glomerulopathy, and opportunistic infections after
recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J renal transplantation. N Engl J Med 308:307, 1983.
Transplant 8:984, 2008. 123. George MJ, Snydman DR, Werner BG, et al: The independent role of cytomegalovi-
91. Dierickx D, Tousseyn T, Requilé A, et al: The accuracy of positron emission tomog- rus for invasive fungal infections in orthotopic liver transplant recipients. Boston
raphy in the detection of post-transplant lymphoproliferative disorder. Haematologica Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc.
98:771, 2013. Gaithersburg, Maryland. Am J Med 103:106, 1997.
92. MacGinnitie AJ, Geha R: X-linked lymphoproliferative disease: Genetic lesions and 124. Tindall B, Cooper DA, Donovan B, Penny R: Primary human immunodeficiency infec-
clinical consequences. Curr Allergy Asthma Rep 2:361, 2002. tion. Clinical and serologic aspects. Infect Dis Clin North Am 2:329, 1988.
93. Cohen JI: Benign and malignant Epstein-Barr virus-associated B-cell lymphoprolifera- 125. Vanhems P, Allard R, Cooper DA, et al: Acute human immunodeficiency virus type 1
tive diseases. Semin Hematol 40:116, 2003. disease as a mononucleosis-like illness: Is the diagnosis too restrictive? Clin Infect Dis
94. Yachie A, Kanegane H, Kasahara Y: Epstein-Barr virus associated T-/natural killer cell 24:965, 1997.
lymphoproliferative diseases. Semin Hematol 40:124, 2003. 126. Rosenberg ES, Caliendo AM, Walker BD: Acute HIV among patients tested for mono-
95. Kawa K, Okamura T, Yasui M, et al: Allogeneic hematopoietic stem cell transplanta- nucleosis [letter]. N Engl J Med 340:969, 1999.
tion for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease. Crit Rev 127. Walensky RP, Rosenberg ES, Ferraro MJ, et al: Investigation of primary human immu-
Oncol Hematol 44:251, 2002. nodeficiency virus infection in patients who test positive for heterophile antibody. Clin
96. Cheng WM, Chan KH, Chen HL, et al: Assessing the risk of nasopharyngeal cancer on Infect Dis 33:570, 2001.
the basis of EBV antibody spectrum. Int J Cancer 97:489, 2002. 128. Dalman J, Puertas MC, Azuara M, et al: Contribution of immunologic and virological
97. Moss DJ, Khanna R, Bharadwaj M: Will a vaccine to nasopharyngeal carcinoma retain factors to the extremely severe primary HIV type 1 infection. Clin Infect Dis 48:229,
orphan status? Dev Biol 110:67, 2002. 2009.
98. Lee ES, Locker J, Nalesnik M, et al: The association of Epstein-Barr virus with smooth 129. Steeper TA, Horwitz CA, Ablashi DV, et al: The spectrum of clinical and laboratory
muscle tumors occurring after organ transplantation. N Engl J Med 332:19, 1995. findings resulting from human Herpesvirus-6 (HHV-6) in patients with mononucle-
99. Oda K, Koda K, Takiguchi N, et al: Detection of Epstein-Barr virus in gastric carcinoma osis-like illness not resulting from Epstein-Barr virus or cytomegalovirus. Am J Clin
cells and surrounding lymphocytes. Gastric Cancer 6:173, 2003. Pathol 93:776, 1990.
100. Murray PG, Young LS: Epstein-Barr virus infection: Basis of malignancy and potential 130. Li IW, To KK, Tang BS, et al: Human metapneumonia virus infections in a human
for therapy. Expert Rev Mol Med 15:2001, 2001. immunocompetent adult presenting as mononucleosis-like illness. J Infect 56:389,
101. Malouf MA, Chajed PN, Hopkins P, et al: Anti-viral prophylaxis reduces the incidence 2008.
of lymphoproliferative disease in lung transplant recipients. J Heart Lung Transplant 131. Andersson J, Britton S, Ernberg I, et al: Effect of acyclovir on infectious mononucleosis:
21:547, 2002. A double-blinded, placebo-controlled study. J Infect Dis 153:283, 1986.
102. Greenspan JS, Greenspan D, Lennette ET: Replication of Epstein-Barr virus within epithe- 132. Torre D, Tambini R: Acyclovir for treatment of infectious mononucleosis: A meta-analysis.
lial cells of hairy oral leukoplakia an AIDS associated lesion. N Engl J Med 332:19, 1986. Scand J Infect Dis 31:543, 1999.
103. Sokal EM, Hoppenbrouwers K, Vandermeulen C, et al: Recombinant gp350 vaccine for 133. Collins M, Fleisher G, Kreisberg J, Fager S: Role of steroids in the treatment of infec-
infectious mononucleosis. A phase 2 randomized, double blind, placebo controlled trial tious mononucleosis in the ambulatory college student. J Am Coll Health 33:101, 1984.
to evaluate the safety, immunogenicity, efficacy of Epstein-Barr virus vaccine in healthy 134. Chan SC, Dawes PJ: The management of severe infectious mononucleosis tonsillitis and
young adults. J Infect Dis 196:1749, 2007. upper airway obstruction. J Laryngol Otol 115:973; 2001.

Kaushansky_chapter 82_p1261-1272.indd 1271 9/18/15 10:06 AM